NASDAQ:GHRS

GH Research (GHRS) Stock Forecast, Price & News

$11.98

+0.33 (+2.83%)

(As of 06/2/2023 ET)

Compare

Today's Range: $11.73
▼
$12.24
50-Day Range: $7.49
▼
$11.98
52-Week Range: $5.70
▼
$17.41

Volume: 13,318 shs
Average Volume: 67,538 shs
Market Capitalization: $605.23 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $48.25

GH Research MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 302.8% Upside
$48.25 Price Target
Short Interest: Bearish
4.96% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.86
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($1.07) to ($1.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

581st out of 983 stocks

Pharmaceutical Preparations Industry

289th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $48.25, GH Research has a forecasted upside of 302.8% from its current price of $11.98.
Amount of Analyst Coverage
GH Research has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.96% of the float of GH Research has been sold short.
Short Interest Ratio / Days to Cover
GH Research has a short interest ratio ("days to cover") of 18.6, which indicates bearish sentiment.
Change versus previous month
Short interest in GH Research has recently increased by 5.79%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
GH Research does not currently pay a dividend.
Dividend Growth
GH Research does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GHRS.

3.8

News and Social Media Coverage

News Sentiment
GH Research has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for GH Research this week, compared to 1 article on an average week.
Search Interest
3 people have searched for GHRS on MarketBeat in the last 30 days.
MarketBeat Follows
5 people have added GH Research to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GH Research insiders have not sold or bought any company stock.
Percentage Held by Insiders
41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
62.55% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for GH Research are expected to decrease in the coming year, from ($1.07) to ($1.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GH Research is -22.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GH Research is -22.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GH Research has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GH Research (NASDAQ:GHRS) Stock

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Stock News Headlines

June 1, 2023 | americanbankingnews.com

GH Research (NASDAQ:GHRS) Trading Down 5.8%

May 17, 2023 | americanbankingnews.com

GH Research PLC Expected to Post FY2027 Earnings of $0.00 Per Share (NASDAQ:GHRS)

June 3, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 15, 2023 | americanbankingnews.com

JMP Securities Raises GH Research (NASDAQ:GHRS) Price Target to $49.00

May 14, 2023 | americanbankingnews.com

GH Research (NASDAQ:GHRS) Shares Gap Up After Analyst Upgrade

May 12, 2023 | msn.com

JMP Securities Maintains GH Research (GHRS) Outperform Recommendation

May 12, 2023 | msn.com

HC Wainwright & Co. Reiterates GH Research (GHRS) Buy Recommendation

May 11, 2023 | msn.com

GH Research: Q1 Earnings Insights

June 3, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

May 11, 2023 | markets.businessinsider.com

GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer

May 11, 2023 | finanznachrichten.de

GH Research PLC: GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 11, 2023 | finance.yahoo.com

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

April 26, 2023 | americanbankingnews.com

BELLUS Health (NASDAQ:BLU) versus GH Research (NASDAQ:GHRS) Financial Comparison

April 5, 2023 | msn.com

Compass Pathways, GH Research Among Top Psychedelic Movers Of Today

April 5, 2023 | reuters.com

Unilever Ghana Ltd

March 16, 2023 | seekingalpha.com

GH Research (GHRS) Investor Presentation - Slideshow

March 13, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Janux Therapeutics Inc (JANX), GH Research (GHRS)

January 11, 2023 | markets.businessinsider.com

2 Psychedelics Companies Tout Advanced Clinical Trials, Progress With Key Products

November 27, 2022 | news.yahoo.com

A new General Hospital: Turning an iconic L.A. landmark into homeless housing

November 10, 2022 | finanznachrichten.de

GH Research PLC: GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

November 10, 2022 | finance.yahoo.com

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

October 8, 2022 | health.usnews.com

Massachusetts General Hospital

September 28, 2022 | reuters.com

GHRS.OQ - | Stock Price & Latest News | Reuters

August 23, 2022 | finance.yahoo.com

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022 | finance.yahoo.com

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

March 28, 2022 | finance.yahoo.com

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

March 18, 2022 | msn.com

Field Trip Health, Allied Among Top Psychedelic Movers Of Today

See More Headlines

GHRS Price History

30 days | 90 days | 365 days | Advanced Chart

GHRS Company Calendar

Last Earnings: 5/11/2023
Today: 6/02/2023
Next Earnings (Estimated): 8/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GHRS
CUSIP: N/A
CIK: 1855129
Web: www.ghres.com
Phone: 212-450-4000
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $48.25
High Stock Price Forecast: $66.00
Low Stock Price Forecast: $33.00
Forecasted Upside/Downside: +302.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -13.73%
Return on Assets: -13.48%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 24.81
Quick Ratio: 24.81

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.79 per share
Price / Book: 2.50

Miscellaneous

Outstanding Shares: 50,520,000
Free Float: 29,504,000
Market Cap: $605.23 million
Optionable: Not Optionable
Beta: 0.73

Key Executives

Mr. Florian Schonharting M.Sc. (Econ) (Age 53)
Co-Founder & Non-Exec. Chairman

Mr. Theis Terwey M.D. (Age 45)
Co-Founder & CEO

Mr. Magnus Halle (Age 24)
Co-Founder & MD of Ireland

Ms. Julie Ryan A.C.A. (Age 36)
VP of Fin.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GHRS Stock - Frequently Asked Questions

Should I buy or sell GH Research stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GH Research in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GHRS shares.
View GHRS analyst ratings or view top-rated stocks.
What is GH Research's stock price forecast for 2023?: 4 equities research analysts have issued 12-month price targets for GH Research's shares. Their GHRS share price forecasts range from $33.00 to $66.00. On average, they anticipate the company's stock price to reach $48.25 in the next year. This suggests a possible upside of 302.8% from the stock's current price.
View analysts price targets for GHRS or view top-rated stocks among Wall Street analysts.
How have GHRS shares performed in 2023?: GH Research's stock was trading at $9.72 at the beginning of the year. Since then, GHRS shares have increased by 23.3% and is now trading at $11.98.
View the best growth stocks for 2023 here.
Are investors shorting GH Research?: GH Research saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,280,000 shares, an increase of 5.8% from the April 30th total of 1,210,000 shares. Based on an average trading volume of 68,900 shares, the short-interest ratio is currently 18.6 days. Approximately 5.0% of the company's shares are short sold.
View GH Research's Short Interest.
When is GH Research's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 22nd 2023.
View our GHRS earnings forecast.
How were GH Research's earnings last quarter?: GH Research PLC (NASDAQ:GHRS) announced its earnings results on Thursday, May, 11th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.03.

What ETFs hold GH Research's stock?: ETFs with the largest weight of GH Research (NASDAQ:GHRS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL).iShares MSCI Ireland ETF (EIRL).
When did GH Research IPO?: (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.
What is GH Research's stock symbol?: GH Research trades on the NASDAQ under the ticker symbol "GHRS."
Who are GH Research's major shareholders?: GH Research's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (8.46%), Mirae Asset Global Investments Co. Ltd. (0.19%), Geode Capital Management LLC (0.10%), AdvisorShares Investments LLC (0.09%), PEAK6 Investments LLC (0.04%) and Renaissance Technologies LLC (0.02%).
How do I buy shares of GH Research?: Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GH Research's stock price today?: One share of GHRS stock can currently be purchased for approximately $11.98.
How much money does GH Research make?: GH Research (NASDAQ:GHRS) has a market capitalization of $605.23 million. The company earns $-22,460,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis.
How can I contact GH Research?: The official website for the company is www.ghres.com. The company can be reached via phone at 212-450-4000 or via email at investors@ghres.com.

This page (NASDAQ:GHRS) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial